Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.90K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.90K | -- | -- | -- | -- |
| Cost of Revenue | 45.20K | -- | -- | -- | -- |
| Gross Profit | 17.70K | -- | -- | -- | -- |
| SG&A Expenses | 8.82M | 6.97M | 7.51M | 9.01M | 9.79M |
| Depreciation & Amortization | 750.00K | 750.00K | 750.00K | 750.00K | 750.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.25M | 10.05M | 11.26M | 17.02M | 17.87M |
| Operating Income | -11.19M | -10.05M | -11.26M | -17.02M | -17.87M |
| Income Before Tax | -11.30M | -10.88M | -11.62M | -16.14M | -16.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.30 | -10.88 | -11.62 | -16.14 | -16.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.43M | 1.06M | -- | -- | -- |
| Net Income | -9.87M | -9.81M | -11.62M | -16.14M | -16.31M |
| EBIT | -11.19M | -10.05M | -11.26M | -17.02M | -17.87M |
| EBITDA | -10.14M | -9.05M | -10.26M | -16.02M | -16.87M |
| EPS Basic | -4.48 | -5.17 | -6.44 | -10.29 | -11.61 |
| Normalized Basic EPS | -2.49 | -2.97 | -4.01 | -6.43 | -7.26 |
| EPS Diluted | -4.48 | -5.17 | -6.44 | -10.29 | -11.61 |
| Normalized Diluted EPS | -2.49 | -2.97 | -4.01 | -6.43 | -7.26 |
| Average Basic Shares Outstanding | 8.99M | 7.70M | 7.34M | 6.68M | 5.89M |
| Average Diluted Shares Outstanding | 8.99M | 7.70M | 7.34M | 6.68M | 5.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |